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IMoG4-3IAntimiaobial resistance in Helicobacter pylori. The
European scene
F. Megraud
Laboratoire de Bacteriologie, Hopital Pellegrin, Bordeaux, France
Antimicrobial r~istance is considered to be thc major risk factor for failure
of therapies aiming to eradicate Helicobacter pylori. In Europe. there is a great
diversity in the policies concerning the use ofantibiotics. This diversity may
be reflected in the resistance rate of H. pylori.
A large European survey conducted by Glupczynski et al. in 1997-98
involved 22 centers in 17 countries; 1.305 isolates were tested (mean no./
center: 59) using a standardized Etest methodology. While the global rate of
resistance to clarithromycin was 9.8% [95% Cl (8.3-11.5»), there were
important variations between the northern (4.5'Yo) and thesouthcrn (18.1 %)
parts of the continent, and between children and adult patients. For
metronidazole. the global rate of resistance was 33% [95% CI (30.5-
35.6») with no major regional differences. The drawback of this study. as
for many others, is that only referral centers wcre involved. with a risk of
recruitment bias. For this reason. we began an active survey in Francc where
a large number ofgastroentcrologists were asked to send one positive biopsy
on a given day. In 1997, the rate ofrcsistance to clarithromycin was 14%. and
to metronidazole 24% (N = 525 adults). It has not increased significantly
these last years. A similar survey, but only hospital based. was carried out in
Portugal in 1999. The rate ofresistance to clarithromycin was 11.6% and to
metronidazole 14.3% (N = 545). In northern and central Italy, 200 strains
obtained during a clinical trial in DU patients showed a resistance rate of
11.3% to clarithromycin and 14.7% to metronidazole.
Globally, a trend towards increased resistance can be observed for
macrolide resistance. While amoxicillin resistance seems uncommon, a
strain has been found in the Netherlands, and tolerant strains have been
reported in Italy. These results are arguments for setting up surveillance
systems in the different European countries.
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IMoG6-21 National antibiotic policies in different CEE
countries
V. Krcmery,Jr
School ofPublic Health, University of Tmava, Tmava, Slovakia; School of
Health Administration, University of Scranton, Scranton, PA, United States
ObjediVlK: Increasing consumption of antimicrobial agents and increasing
antibiotic resistance in Central Eastern Europe led to a concern of treat
Health Care antibiotics. Therefore most of 11 surveyed CEE countries
adopted after initial liberalization. all countries included both, national and
hospital based antibiotic policies, including antibiotic cauntees, National
Hospital ATB formularies, restricted prescribing, HMO/Hospital reserved
antibiotics.
Results: Similarities and differences in CEE countries (Slovak Republic,
Czech Republic, Hungary. Austria. Germany. Poland, Croatia. Slovenia,
etc.) are discussed as well as adherence to various guidelines and their impact
to ATB consumption. Four of 11 countries has centralized but 9 of 11
hospital based ATB policies. Numerous antimicrobials are restricted in 8 of
11 countries for hospital use. However, only 3 of 11 CEE countries restrict
ATB (e.g. qiunolones oOrd Generation CEF's) for GP use.
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ITuG7-31 Molecular detection of antibiotic resistance
R. Leclercq
Microbiology, CHU Caen, 14033 Caen cedex, France
A major research effort in clinical microbiology has been the development of
rapid methods for antimicrobial susceptibility testing. The genotypic
approach could offer interesting possibilities to detect antimicrobial resis-
tances since it is rapid and independent from breakpoint categorization
which differs from a country. to another one. DNA probes. including
oligonuclcotide probes, were first used for detection of resistance genes.
Nucleic acid-based amplification techniques have been developped which
improve sensitivity of detection and allows detection of resistance directly
from clinical samples. Recently developped methods. DNA chips. would
allow to use thousands of oligonucleotides in a single reaction. One possible
limitation of these techniques is the observation that not only acqnisition or
mutation ofstructural genes are responsible for resistance, but also regulation
ofgene expression. Also. false positive results are expected in the case ofsilent
genes detected by the genotypic techniques but not expressed.
Applications are mostly devclopped for resistances difficult to detect
phenotypically in rapidly growing bacteria. such as methicillin resistance
in staphylococci or glycopeptidc resistanec in enterococci. or resistance in
fastidious organisms. such as mycobacteria and Helicobacter pylori. In the
latter case. resistances can be detected by PCR done on bacterial DNA
extracted from gastric biopsy material.
Synergistic combination of genotypic and phenotypic techniques should
help to rule out inappropriate therapy. The genotypic approach could help
the physicians to prescribe antibiotics only to patients who need them.
Information provided by the genotypic techniques should help to evaluate
the extent of the resistance determinant pool in outbreaks.
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ITuG10-1\ Taxonomy of new anaerobic bacteria
Hannele Jousimies-Somer
National Public Health Institute, Helsinki, Finland
As a result of 16S rRNA sequencing. major reorganizations among
anaerobic taxa are underway. The gram-negative pigmented Prevotella
now include 8 species. the latest being Pr. nigrescens, Pr. tannerae and Pr.
pallens, The nonpigmented former Mitsuokel/a dentalis and Hallella seregens
were renamed as one species, Prevotella dentalis. The bile-sensitive. oral Pr.
heparinolytica and Pr. zoogleoformans phylogene- tically cluster in B·fragilis-
group. Bacteroides tectum homology group 11 (zoonotic) are genotypically
identical with B. pyogtMs. The bile-resistant B. distasonis clusters with B.
forsythus among PorphyromOllas which currently include 11 pigmented and
one nonpigmented species: P. tatoniae; several new groups awaite inclusion.
Fusobacterium nucleatum currently has 5 subspecies and is very heterogenous;
(phylo)genetic analyses place F. periodonticum within F. nucleatum. F. varium
includes F. pseudonecrophorum. The bile-sensitive, former B. gracilis now are
Campylobaeter gracilis; the bile-resistant variants belog to a new genus
Sutterella as S. wadsworthensis. Capnocytophaga hemolytica, C. granulosa and
Leptotrichia sanquinegens are new species among the capnophilic taxa.
Desulfovibrio fairfieldensis is a new species among the Desulfovibrio and
Anaerobiospirillum thomasii a new spiral, motile organism.
The new Actinomycesspecies include two subspecies ofA. neuii, A. radingae
- A. turicensis complex. A. europaeus, A. slackii, A. graevenitzii and several
other species. A. pyoJlenes and A. bernardiae were recently transferred to the
genus Arcanobacterium. Actinomyces suis and Actinomyces-like organisms from
human origin were reclassified to a new genus ActillObaculum. The genus
Eubacterium sensu stricto is represented by E. limosum and the former E.
alactolyticum was reclassified in a new genus PseuJoramibacter as P. aladolyticus.
Eggerthella lellla was Eubacterium lentum; other new gram-positive genera
include Collinsella, Slackia, Crypto bacterium, Atopobium, Holdemania and
Filifactor. The genus Peptostreptococcus also harbors new species; P. harei, P.
ivorii and P. octavius. Finegoldia magnus and Micromonas micros are new
synonyms of P. magnus and P. micros, respectively.
ITuG10-31 Antibiotic susceptibility of Bacteroides fragllis in
Europe
E. Nagy
Dept. ofClinical Microbiology, Faculty of Medicine, University ofSzeged,
Hungary
Bacteroides fragilis is the most commonly isolated human pathogenic anae-
robic bacterium belonging in the Bacteroides genus. senso stricto. Antibiotic
resistance problems were reported most frequently for members of this
genus during past decades. often without discrimination of isolates on a
species level. Besides the reference agar-dilution method. the determination
of MICs by the Etest has become available for routine laboratories to
evaluate the resistance of clinical isolates of anaerobes more easily.
Antibiotic resistance due to beta-Iactamase activity is observed most
oftenamong B. fragilis and related species. A unique merallo-bera-lactamase
production of B. fragilis is responsible for the resistance of this species to
carbapenems. The presence of the cftA gene, coding the production of this
enzyme. hes been detected by PCR among earbapenem-resisrant and
susceptible strains in different parrs of Europe. The expression of the cfiA
gene was found to be connected with the presence ofIS element•. Decreased
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permeability and modification of the PBPs have also been reported as the
cause ofresistance to cefoxitin, ureidopenicillins and inhibitor combinations.
Clindamycin resistance among Bacteroides species varies in the different parts
of the world. Low numbers of strains among B. fragilis and related species
that are resistant to metronidazole have benn detected in different countries.
The in vitro data indicate that some of the newest fluoroquinolones have
considerable anti-anaerobic effects, including B.fragilis.
ITuG10-41 carbapenem and metronidazole resistance in
Bacteroides tragi/is
M. Hedberg
Dept ofMicrobiology, Pathology and Immunology, Huddinge University
Hospital, Karolinska Institutet, Stockholm, Sweden
Bacteroides fragilis group strains are the microorganisms most often isolated
from patients with anaerobic infections and among the most resistant of all
anaerobes to antimicrobial agents. Imipenem :md metronidazole are two of
the most active antimicrobial agents against the B. fragilis group.
The primary mechanism for resistance to beta-Iactam agents is production
of beta-Iactamases. Carbapenem-hydrolyzing metallo-beta-Iactamases play
an important role in the imipenem resistance of B. fragilis strains. This
enzyme production is encoded by ccrA (or cfiA). Strains resistant to
carbapcnems are rare and usually resistant to other beta-Iactam compounds.
5-Nitroimidazole (metronidazole) resistance appears to be caused by a
combination of decreased antibiotic uptake and decreased nitroreductase
activity. It has been demonstrated that the nim genes confer a moderate level
of resistance to metronidazole in Bacteroides spp. The presence of nim genes
has been shown to occur in strains with MICs 2: t mgfL of metronidazole,
and in contrast, some strains highly resistant (> 32 mg/L) to metronidazole
have been demonstrated to lack these genes. Simultaneous resistance to
imipenem and metronidazole is unusual, and isolates resistant to both agents
are reported sporadically. B.fragilis strains harbouring this kind of resistance
have been isolated from severe infections as well as from faecal samples. Since
options for the treatment of B. fragilis are limited, the appaernace of
multiresistant strains will give rise to a refractory problem in clinical
medicine.
